EXTENSIVE STAGE SMALL CELL LUNG CANCER

This study tests a new treatment called LK101, given together with common immunotherapy drugs (pembrolizumab, durvalumab, or tislelizumab), for people with advanced lung cancer that has not responded to previous treatments. The goal is to see if the combination is safe and tolera…

This early-phase study tests a combination of two drugs, tarlatamab and AB248, in adults with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The main goals are to check safety and find the best dose. About 380 participants will be enr…

This early-phase trial is testing whether combining two drugs, valemetostat and atezolizumab, is safe as maintenance therapy for people with extensive-stage small cell lung cancer. About 24 participants will receive different doses of valemetostat along with a standard dose of at…

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This study tests whether a combination of two drugs, lurbinectedin and serplulimab, can help keep extensive-stage small cell lung cancer from growing after initial chemotherapy. About 30 adults whose cancer has not worsened after four cycles of standard chemo will receive the dru…

This phase 2 trial tests whether adding chest radiotherapy to maintenance immunotherapy (atezolizumab) can better control extensive-stage small cell lung cancer. About 37 adults whose cancer shrank after initial chemo-immunotherapy will receive targeted radiation to the chest alo…

This study tests a new treatment for people with a specific type of advanced small cell lung cancer (SLFN-11 positive). The treatment combines low-dose radiation, chemotherapy, an immunotherapy drug (sugemalimab), and a targeted drug (olaparib). The goal is to see if this combina…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This study tests whether adding the drug bevacizumab to standard chemo-immunotherapy can help people with extensive-stage small cell lung cancer that has spread to the liver. About 39 participants will receive the combination for up to a year. The goal is to see if it delays canc…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) combined with standard immunotherapy (atezolizumab) and sometimes chemotherapy (carboplatin) for people with extensive-stage small cell lung cancer who have not yet been treated. The goal is to see if the combinatio…

This study tests whether a new drug called BNT327, combined with standard chemotherapy, helps people with advanced small-cell lung cancer live longer compared to another approved drug (atezolizumab) plus the same chemo. About 621 adults who have not yet been treated for their can…

This study tests a combination of two drugs, monalizumab and durvalumab, plus chemotherapy for people with small cell lung cancer. The goal is to see if this mix can keep the cancer from growing longer than standard treatment. About 84 adults with either extensive or limited stag…

This early-phase study tests a new drug called ALPS12 in people with extensive-stage small cell lung cancer that has returned after prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 122 participants will ta…

This study tests a new treatment for people with extensive stage small cell lung cancer who have not had treatment before. Participants first get standard chemo-immunotherapy, then a maintenance therapy with two drugs: durvalumab and ceralasertib. The goal is to see if this combi…

This study tests whether adding the drug tarlatamab to standard chemotherapy (durvalumab, carboplatin, etoposide) helps people with untreated extensive-stage small-cell lung cancer live longer. About 330 adults will be randomly assigned to receive either the new combo or standard…

This study tests a new treatment for people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread. The treatment combines the drug tislelizumab with chemotherapy and radiation to the chest. The goal is to see if this combination can help control the c…

This study tests a new drug called tarlatamab, given as a shot under the skin, for people with extensive stage small cell lung cancer that has come back after chemotherapy. The main goals are to check safety and how the body handles the drug. About 220 adults will take part to se…

This study is for people newly diagnosed with extensive-stage small cell lung cancer, a type that has spread. Researchers want to see if adding focused radiation to the standard treatment of durvalumab and chemotherapy can help control the cancer longer. About 49 participants wil…

This study tests if adding trilaciclib before standard chemotherapy can help people with extensive-stage small cell lung cancer live longer. About 302 participants who have already tried other treatments will receive either trilaciclib or a placebo. The goal is to see if trilacic…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study is looking at whether a special test that analyzes immune cells (called T cell repertoire technology) can predict how well a combination of the drug tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. The study will foll…